These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1445664)

  • 1. Phase I cancer trials: limitations and implications.
    Dillman RO; Koziol JA
    Mol Biother; 1992 Sep; 4(3):117-21. PubMed ID: 1445664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethics and errors of clinical trials and the role and place of different types of trial.
    Mathé G; Reizenstein P
    Drugs Exp Clin Res; 1986; 12(1-3):1-9. PubMed ID: 3732046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status and issues in clinical trials of anticancer agents].
    Kojima H
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I trials--clinical studies of antineoplastic agents].
    Takahashi H; Wakui A; Yokoyama M; Oikawa H; Yoshioka T; Matsuoka S
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1477-85. PubMed ID: 1854218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
    Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
    J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Principles and practice of clinical phase I studies].
    Hanauske AR
    Onkologie; 2008; 31 Suppl 2():39-45. PubMed ID: 18487868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Introduction of anticancer agents to phase I clinical trials].
    Shimoyama M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically based phase I trials in cancer chemotherapy.
    Newell DR
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):257-75. PubMed ID: 8040140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.